ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Accessibility StatementSkip Navigation "We're proud to support the advancement of ratutrelvir from discovery through clinical development," said Ilya Baimetov, COO at ChemDiv. "By combining our integrated medicinal chemistry capabilities with Molsoft's rational design tools and Expert Systems' AI-driven predictive pharmacology, we created a differentiated COVID therapeutic with best-in-class potential. Our continued CMC support ensures Traws has the manufacturing infrastructure and analytical capabilities ...